New treatments for Alzheimer's Disease using protein activators
Direct protein phosphatase 2A (PP2A) activators as novel Alzheimer’s Disease (AD) therapeutics
This study is looking at new pills that could help fight Alzheimer's Disease by boosting a protein that may help reduce brain inflammation and other issues related to the condition, and it's testing how well these pills work in different models.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Atux Iskay Group LLC NIH-funded |
| Lab location | 1 site (Plainsboro, United States) |
| Project ID | NIH-11041145 on NIH RePORTER |
What this research studies
This research focuses on developing new compounds that activate protein phosphatase 2A (PP2A) to combat Alzheimer's Disease (AD). By increasing the activity of PP2A, the research aims to address the underlying causes of AD, such as tau phosphorylation and neuroinflammation. The compounds are designed to be taken orally and are expected to reach the central nervous system effectively. The study involves testing these compounds in various models to evaluate their effectiveness in slowing down or preventing the progression of AD.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals aged 65 and older who are experiencing symptoms of Alzheimer's Disease or related dementias.
Not a fit: Patients under the age of 65 or those without symptoms of Alzheimer's Disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative treatments that significantly slow the progression of Alzheimer's Disease, improving quality of life for patients.
How similar studies have performed: While the approach of targeting PP2A is relatively novel, similar strategies in other neurodegenerative conditions have shown promise, indicating potential for success.
Where this research is happening
Plainsboro, United States
- Atux Iskay Group LLC — Plainsboro, United States (Active)
Researchers
- Principal investigator: Ohlmeyer, Michael — Atux Iskay Group LLC
- Study coordinator: Ohlmeyer, Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.